Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma

Y.M. Geurts,S.I.M. Neppelenbroek,B.M.P. Aleman,C.P.M. Janus,A.D.G. Krol,D.J. van Spronsen,W.J. Plattel,J.M. Roesink,K.M.S. Verschueren,J.M. Zijlstra,H.R. Koene,M.R. Nijziel,E.C. Schimmel,E. de Jongh,F. Ong,L.C.J. te Boome,R.S. van Rijn,L.H. Böhmer,B.D.P. Ta,H.P.J. Visser,E.F.M. Posthuma,Y.M. Bilgin,K. Muller,D. van Kampen,C. So-Osman,J.S.P. Vermaat,R.J. de Weijer,M.J. Kersten,F.E. van Leeuwen,M. Schaapveld

DOI: https://doi.org/10.1016/j.esmoop.2024.102248

IF: 6.883

2024-02-01

ESMO Open

Abstract:BACKGROUND: The introduction of rituximab significantly improved the prognosis of diffuse large B-cell lymphoma (DLBCL), emphasizing the importance of evaluating the long-term consequences of exposure to radiotherapy, alkylating agents and anthracycline-containing (immuno)chemotherapy among DLBCL survivors.METHODS: Long-term risk of subsequent malignant neoplasms (SMNs) was examined in a multicenter cohort comprising 2373 5-year DLBCL survivors treated at ages 15-61 years in 1989-2012. Observed SMN numbers were compared with expected cancer incidence to estimate standardized incidence ratios (SIRs) and absolute excess risks (AERs/10 000 person-years). Treatment-specific risks were assessed using multivariable Cox regression.RESULTS: After a median follow-up of 13.8 years, 321 survivors developed one or more SMNs (SIR 1.5, 95% CI 1.3-1.8, AER 51.8). SIRs remained increased for at least 20 years after first-line treatment (SIR ≥20-year follow-up 1.5, 95% CI 1.0-2.2, AER 81.8) and were highest among patients ≤40 years at first DLBCL treatment (SIR 2.7, 95% CI 2.0-3.5). Lung (SIR 2.0, 95% CI 1.5-2.7, AER 13.4) and gastrointestinal cancers (SIR 1.5, 95% CI 1.2-2.0, AER 11.8) accounted for the largest excess risks. Treatment with >4500 mg/m² cyclophosphamide/>300 mg/m² doxorubicin versus ≤2250 mg/m²/≤150 mg/m², respectively, was associated with increased solid SMN risk (hazard ratio 1.5, 95% CI 1.0-2.2). Survivors who received rituximab had a lower risk of subdiaphragmatic solid SMNs (hazard ratio 0.5, 95% CI 0.3-1.0) compared with survivors who did not receive rituximab.CONCLUSION: Five-year DLBCL survivors have an increased risk of SMNs. Risks were higher for survivors ≤40 years at first treatment and survivors treated with >4500 mg/m² cyclophosphamide/>300 mg/m² doxorubicin, and may be lower for survivors treated in the rituximab era, emphasizing the need for studies with longer follow-up for rituximab-treated patients.

oncology